Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009;Le traitement de la leishmaniose viscérale en Europe en 2009. Place de l'amphotéricine B liposomale

Medecine et Maladies Infectieuses

Volumn 39, Issue 10, 2009, Pages 741-744

  Rosenthal, E ^a   Delaunay, P ^a   Jeandel, P Y ^a   Haas, H ^a   Pomares Estran, C ^a   Marty, P ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Leishmaniasis; Liposomal amphotericin B; Visceral

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ANTIRETROVIRUS AGENT; MILTEFOSINE; PAROMOMYCIN;

CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERANCE; EUROPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MORTALITY; PREVALENCE; REVIEW; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EUROPE; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL;

EID: 70350211081     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2009.05.001     Document Type: Review

References (27)

1. World Health Organization. Leishmaniasis disease burden (web page). 2005 [cited 2005 04/27/2005]; Available from: http://www.who.int/leishmaniasis/burden/en/.
2. Pearson R.D., Jeronimo S.M.B., and de Queiroz Sousa A. Leishmaniasis. In: Guerrant R.L., Walker D.H., and Weller P.F. (Eds). Tropical infectious diseases: principles, pathogens and practice (1999), Churchill Livingstone, Philadelphia 797-813
3. Bern C., Hightower A.W., Chowdhury R., Ali M., Amann J., Wagatsuma Y., et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis 11 (2005) 655-662
4. Addy M., and Nandy A. Ten years of kala-azar in west Bengal. Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?. Bull World Health Organ 70 (1992) 341-346
5. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A., et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31 (2000) 1104-1107
6. Gradoni L., Gramiccia M., and Scalone A. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis 9 (2003) 1617-1620
7. Rosenthal E., Marty P., and Cassuto J.P. Visceral leishmaniasis and human immunodeficiency virus (HIV) infection in the south of France. Presse Med 24 (1995) 1666
8. Rosenthal E., Tempesta S., Del Giudice P., Marty P., Desjeux P., Pradier C., et al. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS 15 (2001) 1184-1185
9. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 97 Suppl. 1 (2003) 135-142
10. Berenguer J., Cosín J., Miralles P., López J.C., and Padilla B. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 14 (2000) 2946-2948
11. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6 (2001) 849-854
12. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 (2002) 1739-1746
13. Thakur C.P. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 17 (2001) 67-70
14. Sundar S., Mehta H., Suresh A.V., Singh S.P., Rai M., and Murray H.W. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38 (2004) 377-383
15. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 49 Suppl. 1 (2002) 37-41
16. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28 (1999) 42-48
17. Cascio A., di Martino L., Occorsio P., Giacchino R., Catania S., Gigliotti A.R., et al. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. J Antimicrob Chemother 54 (2004) 217-220
18. Syriopoulou V., Daikos G.L., Theodoridou M., Pavlopoulou I., Manolaki A.G., Sereti E., et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 36 (2003) 560-566
19. Kafetzis D.A., Velissariou I.M., Stabouli S., Mavrikou M., Delis D., and Liapi G. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?. Int J Antimicrob Agents 25 (2005) 26-30
20. Jeandel P.Y., Marty P., Roger P., Fuzibet J.G., and Rosenthal E. Amphotéricine B liposomale en cure courte dans le traitement de la leishmaniose viscérale méditerranéenne de l'adulte non immunodéprimé. Rev Med Interne 28 (2007) 44-45
21. Davidson R.N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G.B., et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 87 (1994) 75-81
22. Laguna F., Videla S., Jiménez-Mejías M.E., Sirera G., Torre-Cisneros J., Ribera E., et al. Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 52 (2003) 464-468
23. López-Vélez R., Videla S., Márquez M., Boix V., Jiménez-Mejías M.E., Górgolas M., et al. Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 53 (2004) 540-543
24. Casado J.L., Lopez-Velez R., Pintado V., Quereda C., Antela A., and Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 20 (2001) 202-205
25. Mira J.A., Corzo J.E., Rivero A., Macias J., De Leon F.L., Torre-Cisneros J., et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 70 (2004) 298-301
26. Bern C., Adler-Moore J., Berenguer J., Boelaert M., den Boer M., Davidson R.N., et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43 (2006) 917-924
27. Rosenthal E., and Marty P. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 49 (2003) 61-68